Cathay Biotech Inc.: history, ownership, mission, how it works & makes money

Founded in 2000 and headquartered in Shanghai's Zhangjiang Hi‑Tech Park, Cathay Biotech has grown from an R&D‑focused start‑up to a publicly traded leader on the STAR Market (ticker 688065, listed 2014) that by 2024 expanded manufacturing to Jinxiang and Wusu and in 2025 launched a joint venture with CATL and Kalai Composites to commercialize bio‑based composites for new energy applications; the vertically integrated company-driven by synthetic biology and bio‑manufacturing from biomass feedstocks to long‑chain diacids, polyamides and composites-reported revenue of 2.96 billion yuan in 2024, up 39.91%, and delivered a further 13.43% revenue increase in Q3 2025, while scaling its capital structure to 720.66 million shares outstanding as of October 31, 2025 (a 10.81% year‑over‑year rise), executing share repurchases (230,366 shares, 0.0319% of capital; cumulative repurchases of 10.5 million yuan) and proposing an employee purchase plan of up to 1.3 million shares (0.18%), attracting institutional holders (~14.68% as of November 2025), exporting products across textiles, pharmaceuticals, auto and electronics markets, and achieving a market capitalization of approximately 34.82 billion yuan as of December 22, 2025-signposts that underscore its mission to advance sustainable, industrial‑scale bio‑materials and the commercial pathways that monetize those innovations.

Cathay Biotech Inc. (688065.SS): Intro

• Founded in 2000 in Shanghai, Cathay Biotech Inc. (688065.SS) specializes in bio-based materials with its headquarters and R&D center located in Zhangjiang Hi‑Tech Park.
• In 2014 the company listed on the Shanghai Stock Exchange STAR Market (ticker 688065), a milestone that expanded its access to capital for R&D and manufacturing scale‑up.
• By 2024 Cathay Biotech expanded production with facilities in Jinxiang and Wusu, strengthening regional manufacturing capacity and supply resilience.
• In 2025 Cathay Biotech formed a strategic joint venture with CATL and Kalai Composites to develop bio‑based composite materials for new‑energy applications, signaling a move into battery and automotive materials markets.
• The company has increased its market presence internationally-exhibiting at global trade shows-and has received industry recognition for bio‑manufacturing innovation and sustainability performance.

• Listed public company on SSE STAR Market: ticker 688065.SS.
• Shareholder base includes institutional investors, strategic industrial partners, and public retail shareholders; strategic collaborations (e.g., CATL) reflect cross‑industry alliances rather than full ownership transfers.
• Corporate governance centers on an R&D‑driven board and executive team located in Shanghai, with manufacturing oversight in provincial facilities (Jinxiang, Wusu).

• Mission: develop and commercialize bio‑based polymers and materials that reduce reliance on fossil feedstocks and enable sustainable applications across packaging, automotive, electronics and energy storage sectors.
• Core technologies: microbial fermentation for bio‑polymers, polymer modification for composites, and downstream compounding tailored to customer specifications.
• R&D footprint: headquartered R&D center in Zhangjiang Hi‑Tech Park focusing on scale‑up, application engineering, and joint innovation with industrial partners (e.g., CATL collaboration for composite battery components).

• Feedstock sourcing: bio‑based intermediates (sugars, bioprocess streams) procured regionally and optimized for fermentation efficiency.
• Biomanufacturing: fermentation and bioconversion produce polymer intermediates; processes scaled in Jinxiang and Wusu plants to meet volume demand.
• Downstream processing: polymer modification, compounding and composite layup tailored for target applications (packaging resins, automotive composites, energy materials).
• Sales & distribution: B2B model selling to industrial OEMs, battery manufacturers, packaging companies and compounders; direct engineering support for qualification and scale adoption.

• Bio‑polymers for packaging (films, molded parts)
• Bio‑based composite materials for automotive and new‑energy applications
• Custom compounded resins and masterbatches for industrial customers

• Product sales (largest): bulk bio‑polymers, compounded materials and composite parts sold to industrial customers.
• Engineering & licensing: application development, material qualification services, and potential licensing of proprietary formulations/processes.
• Strategic joint‑venture projects: co‑development agreements (e.g., with CATL/Kalai) that may include development fees, milestones and supply contracts.
• Export sales and international OEM contracts as adoption of bio‑materials expands.

• Primary R&D & headquarters: Zhangjiang Hi‑Tech Park, Shanghai.
• Production sites: Jinxiang and Wusu (expanded by 2024 to improve throughput and geographical coverage).
• Post‑2025 JV manufacturing: planned pilot and scale lines for bio‑composite production targeting new‑energy applications alongside CATL and Kalai Composites.

• Customer base: packaging manufacturers, automotive suppliers, new‑energy OEMs, battery material producers.
• Strategic partners: CATL and Kalai Composites (JV for bio‑composites), research collaborations via Shanghai innovation ecosystem.
• Competitive edge: integration of fermentation‑based polymer production with composite engineering and targeted industrial partnerships for rapid adoption in high‑growth sectors (e.g., EV batteries).

• Regular participation in international exhibitions showcasing bio‑based polymer and composite solutions.
• Industry awards and accolades for contributions to bio‑manufacturing and sustainable materials (multiple trade recognitions reported in company disclosures and exhibition materials).

Cathay Biotech Inc. (688065.SS): History

• Shares outstanding (Oct 31, 2025): 720.66 million (up 10.81% year-over-year).
• Largest shareholder: Cathay Industrial Biotech Ltd. - proposed share repurchase plan Oct 2024.
• Announced repurchase (Aug 2025): 230,366 shares (0.0319% of total), cumulative repurchase value: ¥10.5 million.
• Institutional ownership (Nov 2025): ~14.68% of shares.
• Employee stock ownership draft (Sep 2025): up to 1.3 million shares (0.18% of total) available for purchase.

• Objectives of repurchase & ESOP: enhance shareholder value, attract/retain talent, align employee incentives with company performance.
• Ownership diversity: combination of strategic corporate holder (Cathay Industrial Biotech Ltd.), institutions (~14.68%), management/employees (via ESOP), and retail investors.

Cathay Biotech Inc. (688065.SS): Ownership Structure

• Mission: Provide diversified green solutions for sustainable industrial development through synthetic biology and bio-manufacturing.
• Core values: Technological innovation, sustainability, industrialization of bio-based new materials, and international collaboration/exposure.
• Strategic focus: Scale-up of bio-manufacturing processes and commercialization of bio-based polymers, intermediates and specialty chemicals.

• R&D-led product pipeline: development from pathway engineering and fermentation optimization to downstream processing and formulation.
• Manufacturing model: pilot-to-commercial scale fermenters with technology transfer to external OEM partners and in-house capacity expansion.
• Revenue drivers: product sales of bio-based materials, contract manufacturing and technology licensing/services.

• Direct product sales: bio-based polymers, biochemicals and specialty intermediates sold to industrial customers.
• Contract manufacturing & toll fermentation: leveraging fermentation assets to produce for third parties.
• Licensing & tech services: selling pathway designs, process optimization and scale-up know-how.
• Strategic partnerships: co-development agreements with industrial players to secure off-take and scale.

• Aligns with global carbon neutrality targets by replacing petrochemical feedstocks with bio-based alternatives.
• Participates in international exhibitions to showcase innovations and secure cross-border customers and partners.
• Aims to lead bio-manufacturing industrialization by expanding capacity, improving yields and lowering cost-per-kg of bio-materials.

Cathay Biotech Inc. (688065.SS): Mission and Values

• Feedstock and biomass sourcing: securing lignocellulosic and sugar-based raw materials from regional suppliers to ensure steady input quality and cost control.
• Biological conversion: deploying engineered microbial strains and fermentation platforms to convert biomass into bio-based monomers and intermediates.
• Chemical upgrading and polymerization: transforming bio-monomers into polyamides and composite resins via in-house polymer chemistry and compounding facilities.
• Composite fabrication and finishing: integrating bio-polymers with fibers and additives to make structural composites for automotive, electronics and energy storage enclosures.

• R&D footprint: centralized R&D lab in Shanghai with multidisciplinary teams in strain engineering, process engineering and materials science.
• Digital and automation integration: PAT (process analytical technology), PLC/SCADA systems and data-driven process optimization are applied to reduce variability and scale reliably.
• IP and pilot lines: pilot fermenters and demonstration compounding lines accelerate commercialization of new bio-based polyamides and composites.

• Joint venture with CATL: development of bio-based composite materials tailored to battery pack components and structural parts for new energy vehicles and energy storage systems.
• Partnerships with Kalai Composites and other materials integrators: co-development of fiber-reinforced bio-composites for lightweighting and flame-retardant specifications.
• Collaborative supply-chain arrangements: securing upstream biomass and downstream OEM qualification pathways.

• Sale of bio-based monomers and intermediates to polymer converters and specialty chemical customers.
• Sale of finished bio-polyamide grades and compounded resins to automotive, electronics and industrial OEMs.
• Supply of composite parts and semi-finished components for battery modules and structural assemblies via JV and contract manufacturing.
• Technology licensing and custom development contracts for specialized bio-manufacturing processes.

• Advanced process control and digital twins for fermentation and polymerization lines.
• Automated material handling and compounding to ensure consistency and reduce labor intensity.
• Data-driven quality assurance to meet OEM specifications for battery and automotive suppliers.

Cathay Biotech Inc. (688065.SS): How It Works

• Founded to commercialize bio-based chemical technologies, Cathay Biotech has evolved from specialty chemical producer to an integrated bio-based materials manufacturer.
• Listed on the Shanghai Stock Exchange (688065.SS), the company's ownership structure includes institutional and retail shareholders typical of A-share listings, with strategic partnerships and joint ventures forming part of its capital and operational ecosystem.

• Mission: develop and scale sustainable, bio-based materials to replace petroleum-derived intermediates in multiple downstream industries.
• Strategic pillars: R&D-driven product development, vertical integration of bio-based diacid and polymer production, international market expansion, and collaboration with energy and materials leaders to enter new application areas.

• Feedstocks and bioprocessing: uses fermentation and downstream chemical conversion to produce long-chain diacids and monomers from renewable feedstocks.
• Polymerization and compounding: converts diacids and related monomers into polyamides, specialty resins and composite prepregs through in-house polymerization and compounding lines.
• Product qualification and customization: technical services and application development for textiles, automotive, electronics and specialty consumer goods to meet end-customer performance and sustainability criteria.
• Manufacturing footprint and exports: production facilities designed for scale and export-oriented supply chains to reach international customers.

• Primary revenue streams:
  • Sale of bio-based long-chain diacids and monomers to polymer and specialty chemical manufacturers.
  • Sale of bio-based polyamides and engineered polymers to textile, automotive, electronics and consumer-goods OEMs and suppliers.
  • Composite materials and value-added compounded products for high-performance and new-energy applications.
• Industry end-markets served:
  • Textiles and apparel (bio-based polyamides for fibers and yarns)
  • Pharmaceuticals and perfumes (specialty diacids and intermediates)
  • Automotive and new energy (engineering plastics, composites, and prepregs)
  • Electronic appliances and consumer goods (engineered resins)
• International sales and exports expand addressable market and provide foreign-currency revenue streams.
• Strategic joint ventures and partnerships drive new product commercialization and access to growth sectors - notably a 2025 joint venture with CATL and Kalai Composites to commercialize bio-based composite materials for the new energy sector, creating new revenue channels tied to EVs and energy storage applications.
• Demand drivers: sustainability mandates, corporate procurement of eco-friendly materials, and rising acceptance of bio-based polymers across industries.

• Direct sales to industrial customers and OEMs, supported by technical service teams for material qualification and scale-up.
• Export channels and distributor networks to serve overseas textile, chemical and automotive markets.
• Collaborative commercialization via JV partners (e.g., CATL/Kalai Composites) to access OEM pipelines in the new energy and EV supply chains.

• Value proposition: lower carbon footprint and renewable-sourced performance polymers positioned to replace petrochemical analogues.
• R&D orientation and vertical integration reduce input cost exposure and enable customized formulations for high-margin applications.

Cathay Biotech Inc. (688065.SS): How It Makes Money

• Market capitalization: ~34.82 billion yuan (as of December 22, 2025).
• Reported revenue growth: +39.91% in 2024, reflecting accelerated demand for sustainable materials.
• Strategic joint ventures and off-take agreements (e.g., with CATL and Kalai Composites) that secure long-term volume and price stability.
• Sales channels: direct industrial supply contracts, OEM partnerships, and specialized composite product lines.
• Technology licensing and value-added services for customers integrating bio-based polymers into product designs.